Compare NetFlix Inc (NFLX) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NetFlix Inc vs State Street SPDR S&P Biotech ETF — how do they compare? NetFlix Inc trades at $70.3 (market cap $298.01B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: NetFlix Inc is far larger — about 29.5× State Street SPDR S&P Biotech ETF's market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, NetFlix Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold NetFlix Inc for 125 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| NFLX | XBI | |
|---|---|---|
Market Cap | $298.01B | $10.11B |
Volume | 45,805,108 | 12,903,266 |
Sector | Media | Broad Market / Factor |
52-Week High | $124.13 | $169.55 |
52-Week Low | $67.06 | $104.99 |
Typical Hold Time | 125 Days | 38 Days |
Enterprise Value | $303.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Netflix (NFLX) trades at $71.58, up 2.7% with strong fundamentals including 49.5% ROE and consistent earnings beats. The stock faces technical headwinds with bearish moving averages despite positive sentiment from institutional buying. Recent news highlights Netflix's live sports strategy and content investments, while analyst consensus remains bullish with a $89.78 price target representing 25% upside potential from current levels.
Netflix presents a compelling growth story with expanding profit margins and robust cash flow generation. Key risks include intensifying streaming competition and content cost pressures. The company's scale advantages and pricing power support premium valuation, though technical indicators suggest near-term consolidation may precede further upside.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite oversold RSI conditions. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive catalysts from biotech breakthroughs. Recent news highlights XBI's 76% rally over the past year and ongoing M&A activity driving sector optimism.
Outlook remains cautiously optimistic with potential upside from cancer vaccine developments and sector consolidation, though high volatility and expense ratios relative to broader healthcare ETFs present risks. The ETF's modified equal-weight structure offers diversified exposure to 150+ biotech names, benefiting from improved capital access and clinical trial catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NetFlix Inc
Netflix Inc. is an Internet subscription service for watching television shows and movies. Subscribers can instantly watch unlimited television shows and movies streamed over the Internet to their televisions, computers, and mobile devices and in the United States, subscribers can receive standard definition DVDs and Blu-ray Discs delivered to their homes.
Read more on NFLX →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
